The FDA-approved 68Ga-DOTATATE (NETSPOTTM) for somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors (NETs) has been long suggested to diagnose PCa patients with NED. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.